Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.
Life sciences companies do not do research and development (R&D) like everyone else. With longer innovation cycles, several well-defined layers of regulatory approval and various global hurdles to overcome, patent volumes in the pharmaceutical industry are often dwarfed by those of fast-moving industries such as semiconductors and consumer electronics, which tend to steal the spotlight when it comes to showcasing innovation.
Does that make pharma companies any less innovative? No. In fact, despite the obvious headwinds facing the industry, a growing number of leading pharmaceutical companies have been showing up on Thomson Reuters’ annual Top 100 Global Innovators list.
Measuring innovation
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Thomson Reuters’ annual Top 100 Global Innovators list; patents; innovation; pharmaceutical
